FintechChina
← Sticker Wall
JOURNEY · DETAIL
Fosun's Guo Guangchang: Started from Fudan teacher selling hepatitis B test strips, the 'China Buffett's' trillion-yuan acquisition spree and painful deleveraging
Founded: Guo Guangchang, Liang Xinjun, Wang Qunbin, Fan Wei · Fosun International Limited
JOURNEY
Key Fields
FIELD STAMPSIndustryFintech
RegionChina
ScaleGiant
ChannelOther
Origin
In 1992, 25-year-old Fudan University Youth League cadre Guo Guangchang, along with Liang Xinjun and other colleagues, pooled 38,000 yuan to found Broad Information Technology Consulting, starting out in market research. After shifting to real estate brokerage in 1993 and making their first pot of gold, the team discovered a massive supply-demand gap for hepatitis B diagnostic reagents. They decided to apply their accumulated channels and university technology resources to biopharmaceuticals, marking the starting point of Fosun's 'commercializing scientific research' route.
Milestones
1992
Inception Turning Point
Guo Guangchang left the Fudan University Youth League in 1992 and co-founded Broad Information Technology Consulting with Liang Xinjun with a registered capital of 38,000 yuan. Their first contract was conducting market research for Want Want Foods, earning hundreds of thousands of yuan. In 1993, they transitioned to real estate sales agency, earning their first 10 million yuan and validating the team's sales capabilities.
1993
Productization PMF
In 1993, the team targeted hepatitis B genetic engineering diagnostic reagents, industrializing university research achievements and promoting them to hospital markets nationwide. Around 1995, relying on hepatitis B test strips and other diagnostic products, they earned their first 100 million yuan. 'Fosun' (a homophone for Fudan Star) was established as a result, and pharmaceuticals became their foundational pillar for the next thirty years.
1998
Listing Growth
Fosun Pharma (formerly Fosun Industrial) was listed on the Shanghai Stock Exchange in August 1998, becoming one of Shanghai's first batch of private listed companies, raising about 350 million yuan. This opened up a dual-drive model of 'industry + capital', followed by equity investments in pharmaceutical assets such as Sinopharm Group.
2007
Full Listing Growth
Fosun International completed its overall listing on the Stock Exchange of Hong Kong in July 2007, raising about 12.8 billion HKD. Guo Guangchang entered the ranks of billionaires, and subsequently launched a global shopping spree under the slogan 'Combining China's growth momentum with global resources': acquiring a stake in Club Med in 2010, purchasing Portuguese insurer Fidelidade in 2014, and capturing France's Cirque du Soleil in 2015, with cumulative overseas M&A investment exceeding 220 billion yuan at its peak.
2017
High-Leverage Expansion Failure
Fosun entered fields such as baijiu, fashion, and mining with funds on the scale of about 40 billion yuan, acquiring equity in Tsingtao Brewery, Shede Spirits, Lanvin Group, etc. The group's total debt once exceeded 650 billion yuan, with a high proportion of short-term debt. Cash flow was highly dependent on asset shuffling and continuous refinancing, and the 'buy insurance, buy consumption' model planted liquidity landmines. This period lasted from 2017 to 2019.
2022
Liquidity Crisis Failure
In 2022, Moody's downgraded Fosun International's rating and placed it under negative review. Domestic bonds were dumped, prices of multiple 'Fosun-affiliated' bonds plummeted, and market rumors spread of a debt repayment gap scaling hundreds of billions; Fosun was forced into a 'cutting off the arm to survive' mode, reducing its holdings in Tsingtao Brewery, Fosun Pharma, P&C Insurance of China, and other assets.
2023
Deleveraging Turning Point
Over three years, Fosun recovered over 80 billion yuan in cash through cumulative asset sales, including clearing out its stake in Tsingtao Brewery, selling equity in Hainan Mining and Nanjing Nangang, and exiting German private bank HAL; Guo Guangchang publicly stated 'no longer expanding the balance sheet', strategically contracting back to three core segments: pharmaceuticals, health, and happiness. However, impairment losses from acquired assets like baijiu dragged down performance. This period lasted from 2023 to 2025.
2026
Focusing on Core Business Turning Point
In 2026, Fosun projected a previous year's loss of over 21.5 billion yuan, and Guo Guangchang's wealth shrank by about 37 billion yuan over five years. Meanwhile, vaccine assets were spun off for a capital market listing (having previously secured 9.68 million yuan in Pre-IPO financing), and Henlius's profitability continued to rise, entering a global sales realization period. In his 2026 letter to shareholders, Guo Guangchang proposed 'breaking with the old to foster the new, gathering strength for rebirth', attempting to rebuild credit by focusing on pharmaceutical innovation.
Turning Points
- In 1993, abandoning pure consulting to engage in hepatitis B diagnostic reagents enabled Fosun to find its first core business capable of generating sustainable cash.
- The 2007 overall listing in Hong Kong secured an international capital ticket, transforming a private enterprise group into a globalized financing platform.
- Around 2010, initiating global M&A shifted the focus from 'selling products' to 'buying assets'. While completely changing the model, this also planted the gene of high leverage.
- The 2002 bond market sell-off triggered a liquidity crisis, turning Fosun from buying to selling, and reversing its strategic direction by 180 degrees.
- In 2026, with the vaccine spin-off IPO and Henlius accelerating global expansion, Fosun staked all its chips for a comeback back on its pharmaceutical origins.
Failures & Pitfalls
- The baijiu bet starting in 2017 (successively acquiring stakes in Tsingtao Brewery, Jinhui Liquor, and Shede Spirits) failed to generate synergies during the baijiu industry downturn cycle; instead, it became a major impairment source for the massive pre-announced losses in 2025.
- A large number of fashion and entertainment assets among the 220 billion yuan in overseas M&As (such as Lanvin parent company Lanvin Group) suffered long-term losses or sharp drops in market value, validating the vulnerability of 'buying expensive assets + high leverage' in a rising interest rate cycle.
- During the 2022 liquidity crisis, Fosun's system suffered a double-kill in market value and bond prices, and Guo Guangchang's personal wealth subsequently shrank by about 37 billion yuan, shattering the 'China Buffett' aura.
- All-encompassing expansion pushed the group's total debt peak past 650 billion yuan, forcing it to sell high-quality cash-flow assets like Nangang and P&C Insurance of China to save itself, missing the window for investing in pharmaceutical innovation.
关键成功要素
- Earning its first 100 million yuan through high-margin pharmaceutical products like hepatitis B diagnostic reagents relied on identifying supply-demand gaps and commercializing university technology channels.
- Early listing (Fosun Pharma in 1998, Fosun International in 2007) leveraged the capital market to amplify industrial cash flow.
- The M&A logic of 'combining China's growth momentum with global resources' worked during the domestic demand dividend period, but its leverage costs were fully exposed in interest rate and exchange rate cycles.
- Decisively cutting losses by selling over 80 billion yuan worth of assets over three years post-crisis proved that staying alive is more important than saving face.
- Finally contracting back to the three core pillars of pharmaceuticals, health, and happiness, and acknowledging the boundaries of its circle of competence.
Lessons
- Diversified group expansion must be matched with low-leverage or long-duration funding; funding long-term investments with short-term debt is systemic suicide.
- 'Financing-driven M&A growth' is a flywheel during asset price upswings, but a noose during downswings.
- When cutting loss-making assets, act quickly; companies you are reluctant to sell will cost you even your good assets.
- Returning to the core business is not a step backward. After tossing and turning for thirty years, Fosun's most valuable asset remains the pharmaceutical capability established during the hepatitis B test strip era.
- Personal brand mythology (the China Buffett) is completely useless when the bond market fails; cash flow is the only credit.
Core Data
- Total Revenue：Approx. 192.1 billion RMB (based on public disclosure, independent review unverified)
- Peak Total Debt：Exceeding 650 billion RMB (based on public disclosure, independent review unverified)
- Post-Pandemic Deleveraging Asset Realization：Exceeding 80 billion RMB (cumulative sales from 2022-2025) (based on public disclosure, independent review unverified)
- Founder Wealth Shrinkage：Approx. 37 billion RMB (five years from 2021-2026) (based on public disclosure, independent review unverified)
- 2025 Projected Loss：Exceeding 21.5 billion RMB (Fosun International projected loss) (based on public disclosure, independent review unverified)
- Vaccine Asset - Listing Financing：968 million RMB (based on public disclosure, independent review unverified)
- Peak Overseas M&A Investment：Exceeding 220 billion RMB (based on public disclosure, independent review unverified)
- Henlius：Achieved sustained profitability and entered the global volume expansion period (specific amount not listed separately) (based on public disclosure, independent review unverified)
Competitors / Peers
Fosun's benchmark is Buffett's Berkshire Hathaway (a low-leverage model of insurance float + long-term equity investment), but Fosun's debt duration is much shorter and its float stability is much weaker. Domestic comparables include diversified state-owned holding platforms like CITIC Group and China Resources, as well as HNA Group—the latter also expanded through high-leverage M&As and eventually collapsed into bankruptcy reorganization following its 2017-2018 liquidity crisis. Fosun's luck compared to HNA was that it resolutely sold assets after the 2022 crisis, preserving its listed entity and pharmaceutical core assets.